United States — Supreme Court of the United States & GenBioPro

United States — Supreme Court of the United States: The United States — Supreme Court of the United States is considering requests from Abbott Laboratories and GenBioPro to set aside an appellate court's order regarding mifepristone. The court ultimately paused the 5th Circuit's decision, allowing continued mail access to the drug.

GenBioPro: GenBioPro, a manufacturer of a generic version of mifepristone, also received temporary relief from Samuel Alito's order. The company appealed to the United States — Supreme Court of the United States, stating that the 5th Circuit's decision 'unleashed regulatory chaos' and threatened access to mifepristone nationwide.

United States — Supreme Court of the United States: The United States — Supreme Court of the United States temporarily restored broad access to mifepristone, blocking a lower court's restrictions and maintaining the status quo for abortion pill access.

GenBioPro: GenBioPro, a manufacturer of a generic version of mifepristone, also filed an emergency appeal, contributing to the United States — Supreme Court of the United States's decision to restore access.

United States — Supreme Court of the United States: The United States — Supreme Court of the United States previously overturned Roe v. Wade and preserved access to mifepristone in 2024, and is now the likely destination for an appeal of the United States — United States Court of Appeals for the Third Circuit's ruling.

GenBioPro: GenBioPro, a generic Mifepristone manufacturer, stated that the court's decision ignores the United States — Food and Drug Administration's science and decades of safe use of the drug.